SGS plans to expand the offerings in its Poitiers, France facility by adding cell-based bioassays. The move includes investment in the latest generation of flow cytometers and a Biosafety Level 2 (BL-2) suite. SGS has also hired a senior study director with cell-based assay experience in the fields of apoptosis, necrosis, proliferation, oxidative stress, lysosomes, mitochondrial perturbation and extracellular/intracellular factors. The company plans on further recruitment in the next six months ...